Incyte Corporation

Eli Lilly and Company announced that the FDA has approved Olumiant, a once-daily oral therapy, for pediatric patients 12 years of age and older with severe alopecia areata, expanding the drug's U.S. label to include adolescents with severe hair loss. The approval was supported by 36-week results from the ongoing phase III BRAVE-AA-PEDS study, in which 42% of patients receiving Olumiant 4 mg and 27% receiving the 2-mg dose achieved a SALT score of 20 or less at week 36, corresponding to at least 80% scalp hair coverage, compared with 5% for placebo. At the same 36-week mark, 37% of patients on Olumiant 4 mg reached a SALT score of 10 or less, representing at least 90% scalp hair coverage, versus 21% for the 2-mg dose and 2% for placebo. The drug is already approved in several geographies for adults with moderately to severely active rheumatoid arthritis and adults with severe alopecia areata, and in April 2026 the European Commission approved Olumiant for adolescents aged 12 to under 18 with severe alopecia areata. Olumiant, a once-daily oral JAK inhibitor discovered by Incyte and licensed to Lilly, is also approved in the United States to treat hospitalized adults with COVID-19, and per Eli Lilly more than 33,000 patients have been prescribed it in the United States since 2017.

Mission Bio announced that Merck & Co. and Incyte will each present new data generated using its Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit, alongside a third presentation from Mission Bio itself featuring new clinical data in acute myeloid leukemia. Merck scientist Sydney Hart will present functional genomics findings from a targeted DNA and RNA single-cell assay built with Mission Bio's Assay Services team to study how CRISPR-edited genetic variants affect immune cell function in autoimmune and inflammatory disease, work that links target validation to drug development decision-making. Incyte's Erin Crowgey will present new single-cell clinical data on INCA033989, a monoclonal antibody targeting mutant calreticulin-positive cells in essential thrombocythemia and myelofibrosis, generated with a custom Tapestri assay measuring 46 proteins and 37 genes in the same cell, showing depletion of mutant CALR-positive cells and repopulation by wild-type cells with relevant clinical improvements. Mission Bio Chief Medical Officer Zivjena Vucetic will present clinical study data showing single-cell multiomics achieved 93% sensitivity for measurable residual disease in AML compared to 43% for flow cytometry and 71% for other molecular methods, with additional evidence supporting more accurate stratification of relapse-free survival. The three presentations illustrate how single-cell multiomics connects genetic variation to cellular function, characterizes treatment response in individual cell populations, and identifies residual disease with greater resolution across drug development pipelines.

The US FDA on Friday approved Mirum Pharmaceuticals and Incyte's Atebrioz, also known as zilurgisertib, as a treatment for the rare bone condition fibrodysplasia ossificans progressiva, or FOP. The oral activin receptor-like kinase 2 inhibitor is designed to reduce the volume of total new heterotopic ossification in adults and children 12 years and older. Approval was based on results from a cohort of the PROGRESS study that showed at week 24, mean total new heterotopic ossification lesion volume decreased by 3.2 cm³ in patients receiving Atebrioz compared with an increase of 24.6 cm³ in those on placebo, with benefits maintained through week 48 of the open-label extension. FOP is an ultra-rare, progressive genetic disease impacting approximately 300 people in the US and approximately 900 worldwide, characterized by heterotopic ossification in which bone forms in muscles, tendons, ligaments, and other soft tissues.

Incyte plans to present new clinical data from its inflammation and autoimmunity portfolio at the upcoming EADV Congress, spotlighting updates for Opzelura, its ruxolitinib cream, across immune mediated skin diseases studied in recent dermatology trials. The company will also feature new findings on povorcitinib, reflecting progress across multiple dermatological indications under investigation, including atopic dermatitis, hidradenitis suppurativa, prurigo nodularis and vitiligo. Incyte is a US biopharmaceutical company with a reported market value of about $25.7b, focused on discovering and commercializing therapies across major markets like the United States, Europe, Canada, and Japan. The company said the key tests now lie in the next set of pivotal readouts and regulatory decisions for povorcitinib in hidradenitis suppurativa and prurigo nodularis, along with how clinicians ultimately use Opzelura in practice once these EADV insights flow into treatment guidelines and real world prescribing data over 2027 and beyond.

Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte and Biogen as two of his top stock picks, saying he wanted to take a break from the AI capital expenditure theme. Brown praised Biogen for its strong fundamentals and earnings, but the focus here is on Incyte, which is up 22% this year. Incyte, which develops drugs for blood cancers and inflammatory skin diseases, reported a 38% rise in revenue and a 40% jump in net product sales in its latest quarter, beating estimates. Its key product Jakafi saw sales rise 7%, while Opzelura sales increased 24%. The company raised its full-year fiscal 2026 sales guidance by about 7% and lifted the Opzelura outlook by roughly 40%, and it expects about 10 clinical data readouts in the second half of fiscal 2026. Risks include Jakafi's potential loss of exclusivity in 2028 and competition from AbbVie's Rinvoq, which recently won European approval for vitiligo.

Halozyme Therapeutics and Incyte Corporation announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989, a first-in-class monoclonal antibody targeting mutant calreticulin-expressing myeloproliferative neoplasms. Under the agreement, Halozyme will provide its proprietary ENHANZE drug delivery technology, while Incyte will hold an option to nominate two additional targets. Halozyme will receive an upfront payment, milestone payments, and royalties on commercial sales. Both companies reported record second-quarter 2026 results, with Halozyme's revenue up 48% to $481 million and Incyte's total revenue up 38% to $1.67 billion. Halozyme raised its full-year revenue guidance to $1.835–$1.910 billion, and Incyte raised its net sales guidance to $5.13–$5.26 billion.

Several biotech stocks reached 52-week highs on July 28, 2026, driven by catalysts including strong quarterly results. Incyte Corporation rose over 9% to $132.58 after reporting second-quarter revenue of $1.67 billion, a 38% increase from last year, and projecting full-year net sales of $5.13 billion to $5.26 billion. Pulse Biosciences climbed over 8% to $36.29, Shoulder Innovations surged over 15% to $24.54, Bioventus touched $13.30 with a 6% gain, and LB Pharmaceuticals reached $38.62.

S&P 500 futures edged lower in early Tuesday trading while Dow futures ticked up, as the US 10-year Treasury yield hovered near 4.64% ahead of this week's Federal Reserve decision. Markets are pricing in roughly a one-in-three chance of a rate hike now and about a 56% chance by September. US durable goods orders for June rose 0.3% and a core business investment gauge gained 0.9%, signaling continued corporate spending. Among individual movers, IQVIA Holdings jumped 13.94% after its second-quarter earnings and raised guidance, Incyte gained 9.30% on higher full-year sales guidance, and Sherwin-Williams climbed 8.25% following its quarterly results and buyback progress. On the downside, Sandisk fell 14.25%, Corning declined 12.10% after Citi lowered its price target, and Bloom Energy dropped 11.34%.

Incyte Corporation reported second-quarter 2026 adjusted earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2.00, driven by higher product sales. Total revenues reached $1.67 billion, up 38% year over year and above the consensus of $1.46 billion, led by Jakafi sales of $816.7 million and Opzelura sales of $449.7 million, which included a one-time non-cash benefit of $246 million. The company raised its full-year 2026 guidance, now expecting Opzelura net product revenues between $1.05 billion and $1.1 billion, up from the prior range of $750 million to $790 million, and total net product revenues between $5.13 billion and $5.26 billion. Adjusted R&D and SG&A expenses for 2026 are now projected at $4.625 billion to $4.695 billion, compared with the previous guidance of $3.205 billion to $3.375 billion. Incyte shares have rallied 20.3% year to date.

Incyte reported second-quarter 2026 non-GAAP earnings of $3.09 per share, beating analyst estimates by $0.94, while revenue of $1.67 billion exceeded expectations by $180 million. Total revenue rose 38% year-over-year, driven by a 40% increase in total net sales to $1.49 billion. Jakafi and Jakafi XR net sales grew 7% to $817 million, and Opzelura net sales reached $450 million, though excluding a one-time non-cash benefit from a CMS settlement, Opzelura net sales were $204 million, up 24%. The company raised its full-year 2026 total net sales guidance to a range of $5.13 billion to $5.26 billion, reflecting the CMS agreement and strong performance of its Hematology and Oncology portfolio, which saw net sales of $222 million, a 69% increase. Incyte also increased its operating expense guidance, partly due to the acquisition of Vega Therapeutics, which will result in an IPR&D expense of approximately $1.27 billion in the third quarter.

Incyte reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease, and announced the acquisition of VGA039 through the purchase of Vega Therapeutics. The Phase 1/2 results showed broad annualized bleed rate reductions across von Willebrand disease types and bleed categories, including serious gastrointestinal and joint bleeds, with a mechanism targeting Protein S. Latarcibart holds breakthrough, fast track, orphan drug, and rare pediatric disease designations, and is already in a Phase 3 program called VIVID spanning six continents. The acquisition and data give Incyte a clearer path to larger trials and potential global expansion of its hematology portfolio, as the company seeks to reduce reliance on Jakafi and diversify beyond oncology and immunology. Investors will watch for VIVID-6 Phase 3 readouts, safety updates, and regulatory filing timelines, while weighing clinical and regulatory risks against the potential for a commercially relevant once monthly self-administered regimen versus frequent intravenous factor replacement therapies from competitors such as Takeda and CSL.

Halozyme Therapeutics has entered a global collaboration and license agreement with Incyte to develop additional subcutaneous formulations of Incyte's INCA033989, a first-in-class mutant calreticulin-targeted monoclonal antibody for a cancer indication. The partnership will evaluate subcutaneous dosing using Halozyme's proprietary ENHANZE drug delivery technology in patients with mutCALR-expressing myeloproliferative neoplasms. Incyte gains rights to develop and commercialize the ENHANZE technology with its mutCALR program and holds an option to nominate up to two additional targets. Halozyme will receive an undisclosed upfront payment, milestone payments, and royalties on future net sales. Halozyme's royalty revenues reached $240.7 million in the first quarter of 2026, up 43% year over year, driven by demand for partnered products including subcutaneous Darzalex and Phesgo.

Incyte announced complete safety and efficacy data from the Phase 1/2 multidose study of its investigational monoclonal antibody VGA039, or latarcibart, showing an 81% median reduction in annualized bleeding rate across all bleeding categories and patient types with von Willebrand disease. The data, presented at the ISTH 2026 Congress, included all 16 enrolled patients who completed six once-monthly subcutaneous doses. In patients switching from prior intravenous prophylaxis, bleed reductions ranged from 75% to 100%, while among those not previously on prophylaxis with historical annualized bleeding rates above 12, reductions ranged from 46% to 100%, with nearly all achieving reductions greater than 73%. Latarcibart was safe and well tolerated, with three related treatment-emergent adverse events reported: two Grade 2 headaches and one Grade 1 injection site reaction. The pivotal Phase 3 VIVID-6 trial evaluating latarcibart as a potential first targeted therapy for von Willebrand disease is currently enrolling.

Incyte and TG Therapeutics are two fast-growing pharmaceutical stocks attracting investor attention. Incyte reported first-quarter revenue of $1.27 billion, up 21% year over year, driven by Jakafi sales of $758 million and Opzelura sales of $143 million, with adjusted earnings per share of $1.81 beating analyst estimates. The company anticipates four new approvals and launches through early 2027, supported by a pipeline that includes a recent $1.25 billion acquisition of Vega Therapeutics. TG Therapeutics raised its full-year revenue guidance to $925 million after Briumvi generated $194.8 million in first-quarter U.S. sales, and its strong gross margins and growth make it a potential acquisition target for large pharmaceutical companies.

Truist Securities raised its price target on Incyte Corporation from $103 to $105 while maintaining a Hold rating, citing a $246 million non-cash settlement from a dispute with the Centers for Medicare & Medicaid Services over Opzelura's Medicaid rebate classification. The settlement will be added to Opzelura's net sales in the second quarter of 2026. Truist also revised its model to reflect a roughly 5% improvement in Opzelura's gross-to-net ratio, meaning Incyte will retain more revenue after rebates and discounts. Additionally, the firm updated its outlook on VGA039, an experimental drug for von Willebrand disease, projecting it could reach approximately $1 billion in peak worldwide sales by 2036, with international markets contributing around 20% of that total.

Incyte shares reached a 52-week high of $115.56 on June 26, driven by recent regulatory developments for Opzelura. The company reached an agreement with the Centers for Medicare & Medicaid Services resolving litigation over Medicaid rebate rules, resulting in a one-time, non-cash benefit of approximately $246 million expected in the second quarter ending June 30, 2026. Additionally, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of Opzelura cream for moderate atopic dermatitis in adults, which would make it the first steroid-free topical JAK inhibitor available in the European Union for this indication. Incyte also reported positive phase II results for zilurgisertib in fibrodysplasia ossificans progressiva and announced a planned acquisition of Vega Therapeutics for up to $2 billion to strengthen its pipeline.

StockStory identifies Incyte as a cash-producing company with solid fundamentals, while recommending investors turn down Paycom and Oceaneering. Incyte stands out with a trailing 12-month free cash flow margin of 27.6%, annual revenue growth of 19.3% over the past two years, and annual earnings per share growth of 19.4% over the last five years, boosted by share buybacks. Paycom falls short due to subpar billings growth of 9% over the last year, estimated sales growth of 6.6% for the next 12 months, and a failure to increase operating margin. Oceaneering underperforms with stagnating sales over the last ten years, a low gross margin of 17.4%, and a lack of free cash flow generation.

Incyte announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Opzelura cream for the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate. If approved by the European Commission, Opzelura would become the first steroid-free, topical JAK inhibitor treatment option in the European Union for this patient population. The positive opinion is based on results from the pivotal Phase 3 TRuE-AD4 study, which met its co-primary endpoints at Week 8, with a significantly higher proportion of patients on ruxolitinib cream achieving a 75% or greater improvement in the Eczema Area and Severity Index and Investigator's Global Assessment Treatment Success compared to vehicle cream. Efficacy was maintained with as-needed treatment through Week 24, and the cream was well tolerated with no serious infections, major adverse cardiovascular events, malignancies, or thromboses reported. The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization in the European Union.

Syndax Pharmaceuticals ranks as the most likely biotech takeover target following AbbVie's acquisition of Apogee Therapeutics, according to a Wall Street analysis. With a market cap of roughly $1.71 billion, Syndax is the smallest of three highlighted Nasdaq-listed firms and already has two FDA-approved drugs, Revuforj and Niktimvo, generating $64.86 million in total first-quarter revenue, up 223.6% year over year. Its co-commercialization partner Incyte is named as the most logical acquirer, while Nektar Therapeutics and Viking Therapeutics are seen as less urgent targets due to their larger cash reserves and market caps. The Apogee deal has reignited merger and acquisition speculation across the biotech sector, with buyers seeking late-stage clinical data, large addressable markets, and strategic fit in immunology, obesity, or oncology.

Incyte Corporation has outperformed the broader healthcare sector, with its stock rising 6.5% over the past three months compared to a 1.5% gain for the State Street Healthcare Select Sector SPDR ETF. Over the past 52 weeks, INCY surged 43.9%, far exceeding the ETF's 12.1% increase. The company's first-quarter 2026 revenue of $1.3 billion and adjusted earnings per share of $1.81 both topped Wall Street estimates. Analysts hold a consensus Moderate Buy rating on the stock with a mean price target of $111.26, implying a 13.3% upside from current levels.

Japan's Ministry of Health, Labour and Welfare has approved Incyte's Minjuvi in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma. The approval is supported by data from the global Phase II L-MIND study and Japan's Phase Ib/II J-MIND trial, which showed strong response rates and durable clinical benefits with a manageable safety profile. Common side effects included neutropenia and thrombocytopenia. This marks Minjuvi's second approval in Japan, following its earlier authorization for relapsed or refractory follicular lymphoma, and expands treatment options for patients with this aggressive blood cancer.

Mirum Pharmaceuticals and Incyte Corporation reported positive pivotal phase II results for zilurgisertib in fibrodysplasia ossificans progressiva, and the FDA accepted the new drug application with Priority Review, setting a decision date of September 26, 2026. In the PROGRESS study, only 3.1% of patients on zilurgisertib developed new heterotopic ossification lesions at Week 24 versus 16.7% on placebo, an 81% reduction, with a 99.9% reduction in total volume of new lesions. Sustained benefit was seen through Week 48 with no new lesions in those continuing treatment, and the safety profile was favorable with mostly mild to moderate adverse events. Mirum licensed worldwide rights from Incyte, and year to date, Mirum shares have risen 28.5% and Incyte shares 1%, against a 1.4% industry decline.